登录  
 加关注
查看详情
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

青山妩媚

新的一年,新的心情,新的挑战,新的起点...

 
 
 

日志

 
 

Top 15 Pharma and Top 15 Biotech R&D Budgets  

2010-11-24 10:36:13|  分类: Bio-Pharma |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |


Top 15 Pharma R&D Budgets

Over the past few years we have seen enormous changes on the R&D side of the pharma industry. Mergers big and little have spawned plans to shave costs and many, many research jobs. Struggling to clear a path through a dangerous thicket of patent expirations and risky trials to a bright new future, companies have been overhauling development plans and highlighting new disease arenas as they shutter programs for some of their long-term favorites. And the rapid changes have been felt around the globe.

In 2009, according to the EU's newly released Industrial R&D Investment Scorecard, the biopharma companies among the top 1400 companies around the world actually posted an overall increase in R&D spending even as the global economic crunch triggered a setback in research spending among the entire group. With gains in R&D spending in Europe and the U.S. at only 2% and 1.8% respectively, it took a 26.5% hike in Japan to really drive the numbers up. And many increased their budget devoted to R&D with new mergers and acquisitions that often reflected a hefty appetite for new biotech buyouts.

Global R&D Spending, 1996-2009

Source: Kalorama Information

FierceBiotech analyzed the numbers and came up with the top 15 pharma R&D budgets around the world, with some additional insights into the companies' discovery strategies. Next week, we'll tackle the top 15 biotech companies on the list. Click below to get the details on Pharma's 15 biggest spenders.

1. Roche - $8.7B
2. Pfizer - $7.4B
3. Novartis - $7.06B
4. Johnson & Johnson - $6.66B
5. Sanofi-Aventis - $6.25B
6. GlaxoSmithKline -  $5.59B
7. Merck - $5.58B
8. Takeda Pharmaceuticals - $4.64B

9. AstraZeneca - $4.23B
10. Eli Lilly - $4.13B
11. Bristol-Myers Squibb - $3.48B
12. Boehringer Ingelheim - $3.03B
13. Abbott Laboratories - $2.61B
14. Daiichi Sankyo - $1.89B
15. Astellas Pharma - $1.63B



Read more: Top 15 Pharma R&D Budgets - FiercePharma http://www.fiercepharma.com/special-reports/top-15-pharma-rd-budgets#ixzz16ABqWwXS
Subscribe: http://www.fiercepharma.com/signup?sourceform=Viral-Tynt-FiercePharma-FiercePharma

Biotech's Biggest Spenders


Big Pharma is a global business, with a host of players scattered throughout Europe, the U.S. and Asia. But Big Biotech was born and bred in the U.S. And despite considerable international diversification, the industry still has made-in-the-USA stamped into its DNA.

FierceBiotech analyzed the EU's newly released Industrial R&D Investment Scorecard and came up with the top 15 biotech R&D budgets from around the world, with some additional insights into the companies' discovery strategies. Look over the top 15 global biotechs and you'll find 11 that call the U.S. home. The top five are all American. After skipping past a Japanese and Australian company, the first European biotech pops up in 11th place.

Unlike last week's top 15 pharma R&D budgets, you'll find that the numbers get much, much smaller when you turn your gaze to biotech. Several may wind up buying a company or two, but you won't find the kind of mega-M&A frenzy that is completely reshaping the pharma research landscape.

The companies you'll find here, rather, may find themselves on the menu of Big Pharma companies over the coming year. Some already are. Roche's acquisition of Genentech underscored that trend. And Sanofi's slow-motion hostile move on Genzyme drives the message home unmistakably. And it's a hunger to acquire what they've achieved with their R&D budgets that's driving it.


1. Amgen - $2.72B (?1.99B)
2. Biogen Idec - $1.2B (?894M)
3. Gilead Sciences - $849M (?620M)
4. Genzyme - $805M (?588M
5. Celgene - $745M (?544M)
6. Kyowa Hakko Kirin - $478M (?349M)
7. Vertex Pharmaceuticals - $454M (?332M)
8. Life Technologies - $320M (?234M)

9. CSL - $267M (?195M)
10. Amylin Pharmaceuticals - $172M (?126M)
11. Genmab - 123.01M (?90.14M)
12. Cubist Pharmaceuticals - $118.8M (?87.05M)
13. Merial Animal Health - $115M (?84.2M)
14. MannKind - $108.95M (?79.1)
15. Abraxis Biosciences - $107M (?78.4M)



Read more: Biotech's Biggest Spenders - FierceBiotech http://www.fiercebiotech.com/special-reports/biotechs-biggest-spenders?utm_medium=nl&utm_source=internal#ixzz16ACbR5t6
Subscribe: http://www.fiercebiotech.com/signup?sourceform=Viral-Tynt-FierceBiotech-FierceBiotech
  评论这张
 
阅读(769)| 评论(0)

历史上的今天

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2018